Tower Research Capital (TRC)’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $523K | Buy |
4,961
+2,914
| +142% | +$258K | 0.01% | 878 |
|
|
2025
Q4 | $179K | Sell |
2,047
-1,754
| -46% | -$144K | ﹤0.01% | 1521 |
|
|
2025
Q3 | $253K | Sell |
3,801
-1,538
| -29% | -$87.4K | 0.01% | 1300 |
|
|
2025
Q2 | $295K | Buy |
5,339
+5,108
| +2,211% | +$245K | 0.01% | 1436 |
|
|
2025
Q1 | $11.2K | Sell |
231
-7,138
| -97% | -$299K | ﹤0.01% | 3560 |
|
|
2024
Q4 | $284K | Buy |
7,369
+7,009
| +1,947% | +$306K | 0.01% | 1449 |
|
|
2024
Q3 | $16.2K | Sell |
360
-14,316
| -98% | -$578K | ﹤0.01% | 3376 |
|
|
2024
Q2 | $509K | Buy |
14,676
+14,354
| +4,458% | +$420K | 0.01% | 1323 |
|
|
2024
Q1 | $9.31K | Sell |
322
-11,437
| -97% | -$311K | ﹤0.01% | 3866 |
|
|
2023
Q4 | $270K | Buy |
11,759
+4,037
| +52% | +$70.6K | ﹤0.01% | 1854 |
|
|
2023
Q3 | $129K | Buy |
7,722
+4,604
| +148% | +$89.3K | ﹤0.01% | 1777 |
|
|
2023
Q2 | $86.1K | Buy |
3,118
+1,460
| +88% | +$36.5K | ﹤0.01% | 2136 |
|
|
2023
Q1 | $38K | Sell |
1,658
-89
| -5% | -$1.5K | ﹤0.01% | 2756 |
|
|
2022
Q4 | $19K | Sell |
1,747
-25,407
| -94% | -$214K | ﹤0.01% | 3183 |
|
|
2022
Q3 | $229K | Sell |
27,154
-23,569
| -46% | -$223K | ﹤0.01% | 1796 |
|
|
2022
Q2 | $401K | Buy |
50,723
+44,540
| +720% | +$539K | 0.01% | 1275 |
|
|
2022
Q1 | $146K | Sell |
6,183
-2,652
| -30% | -$74.7K | ﹤0.01% | 1961 |
|
|
2021
Q4 | $302K | Sell |
8,835
-3,298
| -27% | -$104K | 0.01% | 1478 |
|
|
2021
Q3 | $215K | Buy |
12,133
+10,087
| +493% | +$430K | 0.01% | 1756 |
|
|
2021
Q2 | $92K | Buy |
2,046
+499
| +32% | +$16.5K | ﹤0.01% | 2499 |
|
|
2021
Q1 | $40K | Sell |
1,547
-9,624
| -86% | -$244K | ﹤0.01% | 3319 |
|
|
2020
Q4 | $225K | Buy |
11,171
+9,834
| +736% | +$212K | 0.01% | 1615 |
|
|
2020
Q3 | $26K | Sell |
1,337
-1,551
| -54% | -$29.1K | ﹤0.01% | 3776 |
|
|
2020
Q2 | $51K | Buy |
+2,888
| New | +$36.2K | ﹤0.01% | 3032 |
|
|
2020
Q1 | – | Sell |
-2,899
| Closed | -$20K | – | 3721 |
|
|
2019
Q4 | $20K | Buy |
+2,899
| New | +$28.8K | ﹤0.01% | 1922 |
|
|
2019
Q3 | – | Sell |
-75
| Closed | -$1K | – | 4436 |
|
|
2019
Q2 | $1K | Buy |
+75
| New | +$829 | ﹤0.01% | 3474 |
|
|
2019
Q1 | – | Sell |
-7,128
| Closed | -$48K | – | 4181 |
|
|
2018
Q4 | $48K | Buy |
7,128
+7,007
| +5,791% | +$55.6K | ﹤0.01% | 1314 |
|
|
2018
Q3 | $1K | Sell |
121
-926
| -88% | -$7.97K | ﹤0.01% | 3610 |
|
|
2018
Q2 | $7K | Sell |
1,047
-247
| -19% | -$1.9K | ﹤0.01% | 2962 |
|
|
2018
Q1 | $11K | Buy |
+1,294
| New | +$24.4K | ﹤0.01% | 2434 |
|
|
2017
Q4 | – | Sell |
-1,750
| Closed | -$31K | – | 3906 |
|
|
2017
Q3 | $31K | Buy |
+1,750
| New | +$24.2K | ﹤0.01% | 2415 |
|
|
2017
Q2 | – | Sell |
-656
| Closed | -$7.01K | – | 3290 |
|
|
2017
Q1 | $9K | Buy |
+656
| New | +$10.6K | ﹤0.01% | 1862 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Tower Research Capital (TRC)'s PTGX Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Protagonist Therapeutics (PTGX) stake by 142% in Q1 2026, buying an estimated $258K and bringing the position to 4,961 shares worth $523K. The position accounts for 0.01% of the portfolio, ranked #878.
Tower Research Capital (TRC) first reported a position in PTGX in Q1 2017 and has held it in 32 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Tower Research Capital (TRC) held 4,961 shares of Protagonist Therapeutics worth $523K as of Q1 2026.
- Tower Research Capital (TRC) bought 2,914 Protagonist Therapeutics shares in Q1 2026, an estimated $258K.
- Protagonist Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #878 holding.
- Tower Research Capital (TRC) first reported a position in Protagonist Therapeutics in Q1 2017 and has held it in 32 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.